Investment Analysts’ Weekly Ratings Updates for Laboratory Corp. of America (LH)

Several brokerages have updated their recommendations and price targets on shares of Laboratory Corp. of America (NYSE: LH) in the last few weeks:

  • 2/9/2018 – Laboratory Corp. of America was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $190.00 price target on the stock. According to Zacks, “LabCorp posted a mixed fourth-quarter with adjusted earnings topping the Zacks Consensus Estimate and net revenues falling short of the mark. On a positive note, strong year-over-year growth in both earnings and revenues were encouraging. LabCorp diagnostics business was solid on the back of acquisitions, organic volume and a favorable currency translation. Also, after several quarters of dull show, Covance Drug Development has been reporting sturdy growth over the past couple of quarters. This uptrend is primarily owing to the Chiltern takeover and robust organic growth. The 2018 guidance looks promising indicating chances of this bullish trend to be maintained through the year. However, the current economic uncertainty including challenging reimbursement scenario for testing labs and utilization weaknesses are looming headwinds for LabCorp. Overall, in the past three months LabCorp has been trading above the broader industry.”
  • 2/9/2018 – Laboratory Corp. of America had its price target raised by analysts at Citigroup Inc from $161.00 to $184.00. They now have a “neutral” rating on the stock.
  • 2/8/2018 – Laboratory Corp. of America was given a new $183.00 price target on by analysts at Robert W. Baird. They now have a “hold” rating on the stock.
  • 2/7/2018 – Laboratory Corp. of America had its “buy” rating reaffirmed by analysts at Craig Hallum. They now have a $204.00 price target on the stock, up previously from $180.00.
  • 2/2/2018 – Laboratory Corp. of America was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 1/29/2018 – Laboratory Corp. of America is now covered by analysts at Goldman Sachs Group Inc. They set a “buy” rating and a $205.00 price target on the stock.
  • 1/24/2018 – Laboratory Corp. of America was given a new $178.00 price target on by analysts at Mizuho. They now have a “hold” rating on the stock.
  • 1/10/2018 – Laboratory Corp. of America was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 1/10/2018 – Laboratory Corp. of America was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Over the past six months LabCorp has been trading above the broader industry. The company’s Diagnostics business continues to remain strong on improving price, mix, acquisition and favorable foreign exchange. Also after several quarters of dull show, Covance Drug Development reported strong growth on the back of the acquisition of Chiltern, strong organic growth and favorable foreign currency translation. An increased 2017 guidance boosts investors’ confidence indicating chances of this bullish trend to be maintained in the fourth quarter too. However, the current economic uncertainty including challenging volume environment for testing laboratories and utilization weaknesses are looming headwinds for LabCorp. Also, the company's revenue growth was constrained by the impact from multiple hurricanes during the last reported quarter.”
  • 1/4/2018 – Laboratory Corp. of America is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $176.00 price target on the stock.
  • 1/3/2018 – Laboratory Corp. of America was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “The current economic uncertainty including challenging volume environment for testing laboratories and utilization weaknesses are looming headwinds for LabCorp. Also, the company's revenue growth was constrained by the impact from multiple hurricanes during the last reported quarter. On a positive note, LabCorp's Diagnostics business continues to remain strong on improving price, mix, acquisition and favorable foreign exchange. Also after several quarters of dull show, Covance Drug Development reported strong growth on the back of the acquisition of Chiltern, strong organic growth and favorable foreign currency translation. An increased 2017 guidance boosts investors’ confidence indicating chances of this bullish trend to be maintained in the fourth quarter too. Over the past six months LabCorp has been trading above the broader industry.”

Shares of Laboratory Corp. of America Holdings (NYSE:LH) opened at $168.08 on Monday. The company has a current ratio of 1.31, a quick ratio of 1.20 and a debt-to-equity ratio of 0.93. Laboratory Corp. of America Holdings has a 52-week low of $133.65 and a 52-week high of $181.71. The company has a market capitalization of $17,110.54, a PE ratio of 13.77, a PEG ratio of 1.47 and a beta of 0.93.

Laboratory Corp. of America (NYSE:LH) last posted its earnings results on Tuesday, February 6th. The medical research company reported $2.45 EPS for the quarter, topping the Zacks’ consensus estimate of $2.38 by $0.07. Laboratory Corp. of America had a return on equity of 16.30% and a net margin of 12.15%. The business had revenue of $2.70 billion for the quarter, compared to analysts’ expectations of $2.70 billion. During the same quarter in the previous year, the firm earned $2.15 earnings per share. The business’s revenue was up 13.2% compared to the same quarter last year. research analysts forecast that Laboratory Corp. of America Holdings will post 11.53 EPS for the current fiscal year.

In related news, Director Adam H. Schechter sold 1,263 shares of the firm’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $169.29, for a total transaction of $213,813.27. Following the transaction, the director now owns 7,297 shares of the company’s stock, valued at $1,235,309.13. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.90% of the stock is currently owned by insiders.

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Receive News & Ratings for Laboratory Corp of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply